Jlohr Brain Health
  • Home
  • About Us
  • Brain Health Diagnoses
  • Resources on this Site
    • Overviews: 9 Aspects of this Diagnoses
    • Drug Discount Services
    • With Each Diagnosis:
      • YouTube Video
      • Book from Library or Amazon
      • Support Group or Service
    • Tables for Patients:
      • Possible Special Education
      • Possible Social Security Disability Income
      • School Aid
    • Tables for Patients or Professionals
      • Overview of 9 Aspects of this Diagnosis
      • First Pages of Diagnoses from the Diagnostic and Statistical Manual and the Codes from the ICD-10 for Diagnosis and Compensation
  • Medical & Educational Downloads
  • Contact Us
Select Page

Glucomannan polysaccharides derived from Pediococcus pentosaceus: From molecular characteristics to inhibition on colonic cancer cells proliferation

by jlohrconsulting | Sep 6, 2025 | Uncategorized

Carbohydr Polym. 2025 Nov 15;368(Pt 1):124113. doi: 10.1016/j.carbpol.2025.124113. Epub 2025 Jul 23. ABSTRACT Extracellular polysaccharides (EPS) from Pediococcus pentosaceus were obtained, followed by investigation of their structural and functional properties....

The Effect of Positive Psychotherapy on Pain Perception, Daily Functioning, and Mental Health in Patients With Fibromyalgia

by jlohrconsulting | Sep 6, 2025 | Uncategorized

Pain Manag Nurs. 2025 Sep 4:S1524-9042(25)00232-2. doi: 10.1016/j.pmn.2025.07.007. Online ahead of print. ABSTRACT BACKGROUND: Fibromyalgia syndrome (FMS) is a complex chronic pain syndrome disorder characterized by several symptoms, including widespread pain,...

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease

by jlohrconsulting | Sep 6, 2025 | Uncategorized

J Prev Alzheimers Dis. 2025 Sep 5:100337. doi: 10.1016/j.tjpad.2025.100337. Online ahead of print. ABSTRACT BACKGROUND: AR1001 is a phosphodiesterase-5 inhibitor that produces improved cognitive performance and reduces amyloid-β and phosphorylated tau burdens in...

Towards causal inference-based antidepressant selection with brain and blood biomarkers

by jlohrconsulting | Sep 6, 2025 | Uncategorized

Neuropsychopharmacology. 2025 Sep 5. doi: 10.1038/s41386-025-02183-3. Online ahead of print. ABSTRACT This report sought to employ multi-modal integration of pre-treatment brain (electroencephalogram, resting-state functional magnetic resonance imaging) and blood...

Estrogen receptor beta in lateral habenula mediates antidepressant effects of estrogen in postpartum-hormone-withdrawal-induced depression

by jlohrconsulting | Sep 6, 2025 | Uncategorized

Mol Psychiatry. 2025 Sep 5. doi: 10.1038/s41380-025-03215-6. Online ahead of print. ABSTRACT Dramatic drop in reproductive hormone, especially estrogen level, from pregnancy to postpartum period is known to contribute to postpartum depression (PPD), but the underlying...
« Older Entries
Next Entries »

Recent Posts

  • Dissociative Drug-Induced Anxiety
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)

Recent Comments